Abstract
To evaluate if timing of chemotherapy with Temozolomide (TMZ) was able to modify the outcome of glioblastoma (GBM), we analyzed two comparable series of supratentorial GBM patients, treated with surgery and radiotherapy, in which the administration of TMZ has been performed in the first group at first relapse and in the second group in newly diagnosed cases. The end-points were the median survival, the time tumor progression (TTP) and also the Karnofsky (KPS) scale and the Mini Mental State Examination (MMSE) scale at follow-up.
From December 1999 to December 2001 30 patients with recurrent GBM received TMZ until progression. From January 2002 to January 2004 38 newly diagnosed patients received a first cycle of TMZ immediately after surgery, and additional cycles after completing radiotherapy until recurrence. In order to obtain a greater drug exposure we adopted a once-daily 10 days schedule of TMZ every 28 days as follows: 150 mg/m2/day (day 1–5) and 75 mg/m2/day (day 6–10).
The first group had a median overall survival of 14 months and a median TTP of 6. The second group had a median survival of 16 months and a median TTP of 10. The difference of TTP was statistically significant (P < 0.001), while the overall survival was not. The values of KPS and MMSE at 12 months demonstrated a better quality of life in the second group (P < 0.01).
Our regimen permitted to cover the therapeutic “window” between surgery and the beginning of radiotherapy in newly diagnosed cases and is well tolerated by the patients with limited side effects. We will propose as alternative option when the concomitant radio-chemotherapic protocol is not feasible.
Similar content being viewed by others
Abbreviations
- TMZ:
-
Temozolomide
- GBM:
-
Glioblastoma
- TTP:
-
Time tumor progression
- MMSE:
-
Mini mental state examination
- PFS:
-
Progression free survival
- MST:
-
Median survival time
- OS:
-
Overall survival
- MGMT:
-
O6-Methylguanine DNA methyltranspherase
References
Brada M, Hoang-Xuan K, Rampling R, Dietrich P-Y, Dirix LY, Macdonald D, Heimans JJ, Zonnenberg BA, Bravo-Marques JM, Henriksson R, Stupp R, Yue N, Bruner J, Dugan M, Rao S, Zaknoen S (2001) Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol 12:259–266
Brandes AA, Ermani M, Basso U, Amistà P, Berti F, Scienza R, Rotilio A, Pinna G, gardiman M, Monfardini S (2001) Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: a phase II study. Ann Oncol 12:255–257
Dinnes J, Cave C, Huang S, Milne R (2002) A rapid and systematic review of the effectiveness of temozolomide for the treatment of recurrent malignant glioma. Br J Cancer 86:501–505
Trent S, Kong A, Short SC, Traish D, Ashley S, Dowe A, Hines F, Brada M (2002) Temozolomide as second-line chemotherapy for relapsed gliomas. J Neurooncol 57:247–251
Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, Brada M, Spence A, Hohl RJ, Shapiro W, Glantz M, Greenberg H, Selker RG, Wick NA, Rampling R, Friedman H, Phillips P, Bruner J, Yue N, Osoba D, Zaknoen S, Levin VAA (2000) phase II study of temozolomide versus procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83:588–593
Athanassiou H, Synodinou M, Maradougakis E, Paraskevaidis M, Verigos C, Misailidou D, Antonadou D, Saris G, Beroukas K, Karageorgis P (2005) Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme. J Clin Oncol 23:2372–2377
Combs SE, Gutwein S, Schulz-Ertner D, van Kampen M, Thilmann C, Edler L, Wannenmacher M, Debus J (2005) Temozolomide combined with irradiation as postoperative treatment of primary glioblastoma multiforme. Strahelenter Onkol 181:372–377
Lanzetta G, Campanella C, Rozzi A, Nappa M, Costa A, Fedele F, Innocenzi G, Gagliardi FM, Salvati M, Minniti G, Frati A, Frati L, Secchione A (2003) Temozolomide in radio-chemotherapy combined treatment for newly diagnosed glioblastoma multiforme: phase II clinical trial. Anticancer Res 23:5159–5164
Stupp R, Dietrich PY, Ostermann Kraljevic S, Pica A, Maillard I, Maeder P, Meuli R, Janzer R, Pizzolato G, Miralbell R, Porchet F, Regli L, de Tribolet N, Mirimanoff RO, Leyvraz S (2002) Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 20:1375–1382
Stupp R, Mason Warren P, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Panzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996
Chibbaro S, Benvenuti L, Caprio A, Carnesecchi S, Pulerà F, Faggionato F, Serino D, Galli C, Andreuccetti M, Buxton N, Gagliardi R (2004) Temozolomide as first-line agent in treating high-grade gliomas: phase II study. J Neuro-Oncol 67:77–81
Gilbert MR, Friedman HS, Kuttesch JF, Prados MD, Olson JJ, Reaman GH, Zaknoen SL (2002) A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy. Neuro-Oncol 4:261–267
Caroli M, Locatelli M, Campanella R, Beretta F, Farina G, Scanni A, Arienta C (2001) Adjuvant chemotherapy after surgey of high grade gliomas: the role of tamoxifen and temozolomide. Neuro-Oncology 3(4):355, Abs no. 353
Caroli M, Beretta F, Campanella R, Locatelli M, Prada F, Farina G, Scanni A, Arienta C (2002) Modified protocol with temozolomide in combination with tamoxifen as adjuvant chemotherapy after surgery of high grade gliomas. Neuro-Oncology 4(suppl 1):S18, Abs no. 71
Stewart LA (2002) Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359:1011–1018
Aoki T, Mizutani T, Ishikawa M, Sugiyama K, Nobuo H (2003) A first feasibility study of temozolomide for Japanese patients with recurrent anaplastic astrocytoma and glioblastoma multiforme. Int J Clin Oncol 8:301–304
Paulsen F, Hoffmann W, Becker G, Belka C, Weinmann M, Classen J, Kortmann RD, Bamberg M (1999) Chemotherapy in the treatment od recurrent glioblastoma multiforme: ifosfamide versus temozolomide. J Cancer Res Clin Oncol 125:411–418
Sipos L, Vitanovics D, Afra D (2004) Temozolomide chemotherapy of patients with recurrent anaplastic astrocytomas and glioblastomas. Ideggyogy Sz 57:394–399
Teixeira MM, Garcia I, Portela M, Cernuda M, Oliveira C, Albano J, Lima L (2002) Temozolomide in second-line treatment after prior nitrosurea-based chemotherapy in glioblastoma multiforme: experience from a Portuguese institution. Int J Clin Pharmacol Res 22:19–22
Wick W, Steinbach JP, Kuker WM, Dichgans J, Bamberg M, Weller M (2004) One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma. Neurology 62:2113–2115
Chinot OL, Barrie M, Frauger E, Dufour H, Branger D, Palmari J, Braguer D, Hoang-Xuan K, Moktari K, Peragut JC, Martin PM (2004) Grisoli F Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly populations. Cancer 101:2208–2214
Brandes AA, Vastola F, Basso U, Berti F, Pinna G, Rotilio A, Gardiman M, Scienza R, Monfardini S, Ermani M (2003) A prospective study on glioblastoma in the elderly. Cancer 97:657–662
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Caroli, M., Locatelli, M., Campanella, R. et al. Temozolomide in glioblastoma: results of administration at first relapse and in newly diagnosed cases. Is still proposable an alternative schedule to concomitant protocol?. J Neurooncol 84, 71–77 (2007). https://doi.org/10.1007/s11060-007-9343-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11060-007-9343-1